08:28 AM EDT, 06/23/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said Monday that the US Food and Drug Administration had approved a label expansion for Illuccix, enabling its use in selecting patients for radioligand therapy prior to taxane chemotherapy to treat prostate cancer.

This latest update allows the use of Illuccix to identify patients who are most likely to respond to prostate-specific membrane antigen, or PSMA-targeted therapy, the company said.

Telix said it expects Illuccix usage to grow by at least 20,000 additional scans annually following the label expansion.

Shares of Telix were down more than 6% in recent premarket activity.